Hr Positive Her2 Negative Breast Cancer clinical trials

Explore recruiting hr positive her2 negative breast cancer clinical trials.

Recruiting hr positive her2 negative breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hr Positive Her2 Negative Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as first-line therapy in patients with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer with aggressive disease criteria. (ABIGAIL)

Spain, Portugal, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Hormonal Receptor (HR)-positive HER2 negative breast cancer patients treated with preoperative ELacestrant and PULSAR adaptive radiotherapy: a phase II study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized low-intervention phase II trial of the AIO working groups breast cancer and quality of life

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED WITH ERIBULIN IN COMBINATION WITH MEN1611 -THE SABINA STUDY-

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

C4391025_AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

Italy, Spain, France, Slovakia, Germany, Sweden +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.” RXPONDER

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hr Positive Her2 Negative Breast Cancer trials by city

Hr Positive Her2 Negative Breast Cancer in Toronto Hr Positive Her2 Negative Breast Cancer in Vancouver Hr Positive Her2 Negative Breast Cancer in Montreal Hr Positive Her2 Negative Breast Cancer in Calgary Hr Positive Her2 Negative Breast Cancer in Edmonton Hr Positive Her2 Negative Breast Cancer in Ottawa Hr Positive Her2 Negative Breast Cancer in Winnipeg Hr Positive Her2 Negative Breast Cancer in Quebec City Hr Positive Her2 Negative Breast Cancer in Hamilton Hr Positive Her2 Negative Breast Cancer in Kitchener Hr Positive Her2 Negative Breast Cancer in London Hr Positive Her2 Negative Breast Cancer in Halifax Hr Positive Her2 Negative Breast Cancer in New York Hr Positive Her2 Negative Breast Cancer in Los Angeles Hr Positive Her2 Negative Breast Cancer in Chicago Hr Positive Her2 Negative Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease